aTyr Pharma, Inc. ( ATYR ) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower - Hagens Berman - aTyr Pharma ( NASDAQ:ATYR )
SAN FRANCISCO, Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- On September 15, 2025, investors in aTyr Pharma, Inc. ( NASDAQ:ATYR ) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of ...
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society ( ERS ) Congress 2025
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society Congress ...
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society ( ERS ) Congress 2025 - aTyr Pharma ( NASDAQ:ATYR )
Clinical benefit for efzofitimod across multiple disease-related health outcomes reported. Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo ( p=0.0226 ) .
aTyr Pharma, Inc. ( ATYR ) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman - aTyr Pharma ( NASDAQ:ATYR )
SAN FRANCISCO, Sept. 25, 2025 ( GLOBE NEWSWIRE ) -- On September 15, 2025, investors in aTyr Pharma, Inc. ( NASDAQ:ATYR ) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of ...
aTyr Pharma, Inc. ( ATYR ) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman - aTyr Pharma ( NASDAQ:ATYR )
SAN FRANCISCO, Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- On September 15, 2025, investors in aTyr Pharma, Inc. ( NASDAQ:ATYR ) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of ...
Top 3 Health Care Stocks That May Explode In September - aTyr Pharma ( NASDAQ:ATYR ) , Boston Scientific ( NYSE:BSX )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
aTyr Pharma, Inc. ( ATYR ) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens Berman - aTyr Pharma ( NASDAQ:ATYR )
SAN FRANCISCO, Sept. 16, 2025 ( GLOBE NEWSWIRE ) -- On September 15, 2025, investors in aTyr Pharma, Inc. ( NASDAQ:ATYR ) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of ...
Goldman Sachs To Rally around 9%? Here Are 10 Top Analyst Forecasts For Tuesday - aTyr Pharma ( NASDAQ:ATYR ) , Accenture ( NYSE:ACN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B of A Securities raised Darden Restaurants, Inc. DRI price target from $253 to $254.
Crude Oil Rises 1%; Manufacturing Activity in New York Falls In September - Robo.ai ( NASDAQ:AIIO ) , aTyr Pharma ( NASDAQ:ATYR )
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.1% on Monday. The Dow traded up 0.06% to 45,856.77 while the NASDAQ rose 0.75% to 22,307.16. The S&P 500 also rose, gaining, 0.37% to 6,608.41. Consumer discretionary shares jumped by 1.9% on Monday.
ATyr Pharma Stock Sinks, Plans FDA Review After Mixed Phase 3 Results - aTyr Pharma ( NASDAQ:ATYR )
ATyr's stock plunges with 34.7 million shares traded vs 4.83 million average after trial misses primary endpoint. 52.6% of efzofitimod patients achieved steroid withdrawal vs 40.2% on placebo ( p=0.0919 ) . Up Next: Wall Street trader's 34-0 strategy goes public this week. See it first →
Nasdaq Gains Over 100 Points; Tesla Shares Spike Higher - aTyr Pharma ( NASDAQ:ATYR ) , AtlasClear Holdings ( AMEX:ATCH )
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday. Following the market opening Monday, the Dow traded up 0.19% to 45,922.93 while the NASDAQ rose 0.63% to 22,280.38. The S&P 500 also rose, gaining, 0.47% to 6,615.11.
New Mountain Finance, Texas Instruments, Analog Devices And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Akso Health ( NASDAQ:AHG ) , Analog Devices ( NASDAQ:ADI )
U.S. stock futures were higher this morning, with the Dow futures gaining more than 50 points on Monday. Shares of New Mountain Finance Corporation NMFC fell sharply in pre-market trading. B of A Securities analyst Derek Hewett downgraded New Mountain Finance from Buy to Underperform and cut the ...
aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid ( OCS ) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters.
aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis - aTyr Pharma ( NASDAQ:ATYR )
Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid ( OCS ) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters.
Why Check-Cap Shares Are Trading Higher By 183%; Here Are 20 Stocks Moving Premarket - Akso Health ( NASDAQ:AHG ) , AtlasClear Holdings ( AMEX:ATCH )
Shares of Check-Cap Ltd. CHEK rose sharply in pre-market trading. MBody AI and Check Cap Ltd announced that they have entered into a definitive merger agreement.
1 Small-Cap Biotech Stock Poised for a Breakout
The next couple of weeks could reveal a great deal about this stock's prospects.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule ...
Behind the Scenes of aTyr Pharma's Latest Options Trends - aTyr Pharma ( NASDAQ:ATYR )
Investors with a lot of money to spend have taken a bullish stance on aTyr Pharma ATYR. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
2 Small-Cap Biotech Stocks Well Positioned for a Breakout
Clinical trial results expected in the weeks ahead could push shares of these small-cap drugmakers through the roof.
Looking At aTyr Pharma's Recent Unusual Options Activity - aTyr Pharma ( NASDAQ:ATYR )
Whales with a lot of money to spend have taken a noticeably bearish stance on aTyr Pharma. Looking at options history for aTyr Pharma ATYR we detected 18 trades. If we consider the specifics of each trade, it is accurate to state that 27% of the investors opened trades with bullish expectations ...
Nvidia To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Friday - aTyr Pharma ( NASDAQ:ATYR ) , C.H. Robinson Worldwide ( NASDAQ:CHRW )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Jefferies raised aTyr Pharma, Inc. ATYR price target from $9 to $17.
3 Innovation Stocks With Parabolic Upside Potential
These three growth stocks might be deeply undervalued.
1 Small-Cap Biotech Stock Poised for a Breakout
This developmental biotech is nearing a key inflection point.
Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday - Alerus Financial ( NASDAQ:ALRS ) , Abercrombie & Fitch ( NYSE:ANF )
U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on Monday. Shares of Alerus Financial Corporation ALRS rose sharply during Monday's session following better-than-expected quarterly results.
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Arrowhead Pharma ( NASDAQ:ARWR ) , Abivax ( NASDAQ:ABVX )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of GE Vernova Inc. GEV rose sharply during Wednesday's session after the company posted better-than-expected second-quarter 2025 earnings and raised its full-year guidance.
aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
SAN DIEGO, July 22, 2025 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ( Nasdaq: ATYR ) ( "aTyr" or the "Company" ) , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the last ...
aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis - aTyr Pharma ( NASDAQ:ATYR )
SAN DIEGO, July 22, 2025 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc.
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
SAN DIEGO, June 26, 2025 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ( Nasdaq: ATYR ) ( "aTyr" or the "Company" ) , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the ...
aTyr Pharma to Present at Upcoming Investor Conferences
SAN DIEGO, May 20, 2025 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ( Nasdaq: ATYR ) , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S.
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society ( ATS ) 2025 International Conference - aTyr Pharma ( NASDAQ:ATYR )
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population.
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis - aTyr Pharma ( NASDAQ:ATYR )
Preclinical data demonstrate ATYR0101's unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the American Thoracic Society ( ATS ) 2025 Respiratory Innovation Summit. SAN DIEGO, May 14, 2025 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc.
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update - aTyr Pharma ( NASDAQ:ATYR )
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment practices for pulmonary sarcoidosis to be ...
aTyr Pharma to Participate in April Investor Conferences - aTyr Pharma ( NASDAQ:ATYR )
SAN DIEGO, April 03, 2025 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ATYR, a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming ...
Is aTyr Pharma ( ATYR ) Stock Outpacing Its Medical Peers This Year?
Here is how Atyr Pharma (ATYR) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update - aTyr Pharma ( NASDAQ:ATYR )
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable safety profile.
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable safety profile. Company to host conference call and webcast today, March 13th ...
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis - aTyr Pharma ( NASDAQ:ATYR )
SAN DIEGO, March 06, 2025 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc.
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference - aTyr Pharma ( NASDAQ:ATYR )
SAN DIEGO, Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ATYR, a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S.
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - enGene Holdings ( NASDAQ:ENGN ) , aTyr Pharma ( NASDAQ:ATYR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society ( ATS ) 2025 International Conference
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. topline data from the study expected in the third quarter of ...
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society ( ATS ) 2025 International Conference - aTyr Pharma ( NASDAQ:ATYR )
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025 Current epidemiology and treatment practices for pulmonary sarcoidosis in the U.S. based on ...
This Toast Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - aTyr Pharma ( NASDAQ:ATYR ) , Nano X Imaging ( NASDAQ:NNOX )
Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Piper Sandler analyst Brent Bracelin initiated coverage on ServiceTitan, Inc.
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - aTyr Pharma ( NASDAQ:ATYR )
SAN DIEGO, Dec. 17, 2024 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ATYR, a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S.
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors - aTyr Pharma ( NASDAQ:ATYR )
SAN DIEGO, Dec. 12, 2024 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ATYR ( "aTyr" or the "Company" ) , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric ...
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update - aTyr Pharma ( NASDAQ:ATYR )
Enrollment completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data expected in the third quarter of 2025. Publication in European Respiratory Journal demonstrated statistically significant difference in time-to-first relapse for corticosteroid use and ...
EyePoint Pharmaceuticals ( EYPT ) Reports Q3 Loss, Lags Revenue Estimates
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -12.50% and 14.79%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
C4 Therapeutics, Inc. ( CCCC ) Reports Q3 Loss, Tops Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of 12.50% and 158.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
aTyr Pharma to Present at Upcoming Investor Conferences - aTyr Pharma ( NASDAQ:ATYR )
SAN DIEGO, Oct. 31, 2024 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ATYR, a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present at several upcoming ...
aTyr Pharma to Participate in September Investor Conferences
SAN DIEGO, Aug. 21, 2024 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ( Nasdaq: ATYR ) , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in ...
aTyr Pharma to Participate in September Investor Conferences - aTyr Pharma ( NASDAQ:ATYR )
SAN DIEGO, Aug. 21, 2024 ( GLOBE NEWSWIRE ) -- aTyr Pharma, Inc. ATYR, a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in several upcoming ...
